Congress in Spain were a major feature of research news last week, including those from Pfizer on it ponsegromab in cancer ...

Drug maker GSK plc (GSK, GSK.L) announced Tuesday that Blenrep (belantamab mafodotin) combinations in relapsed/refractory multiple ...

Leading GSK-3β Inhibitor with a Novel, Multimodal Mechanism of Action in Multiple Refractory Cancer TrialsOrphan Drug Designation in Soft Tissue Sarcomas Expands Company’s Potential to Address Cancers ...

The European Society for Medical Oncology’s annual meeting this week featured the hottest emergent areas of cancer ...

Bispecific antibodies and anti-TIGIT therapies both appear to be writing comeback stories as cancer experts head to Barcelona for the 2024 European Society for Medical Oncology Congress. Radioligand ...

1 American Cancer Society. Cancer Facts & Figures 2024 ... Actuate's lead investigational drug product, elraglusib (a novel GSK-3ß inhibitor), targets molecular pathways in cancer that are involved in ...

according to the American Cancer Society. GSK, in its news release, cited statistics that the five-year survival rate of extensive-stage small cell lung cancer is 3% and that the median overall ...

which is a novel inhibitor of glycogen synthase kinase-3 beta (GSK-3β), a molecule involved in the growth and drug resistance of tumors. The American Cancer Society projects that around 13,590 ...

Obermair calls for his fellow gynecological cancer surgeons to join him in interrogating current standards of practice.

With pivotal trial results and an approval from the FDA, the landscape is changing for patients with small cell lung cancer.

GSK’s Blenrep in combo with BorDex receives China NMPA breakthrough therapy designation to treat relapsed/refractory multiple myeloma: London, UK Saturday, September 14, 2024, 0 ...

Japan’s MHLW accepts for review GSK’s NDA for Blenrep combinations in relapsed/refractory multiple myeloma: London, UK Wednesday, September 18, 2024, 10:00 Hrs [IST] GSK plc a ...